Emetend 150 mg Solution

    Emetend 150 mg Solution

    S4


    1. What EMETEND 150 mg is and what it is used for

    • EMETEND 150 mg contains the active substance fosaprepitant.

    • It is converted to aprepitant in your body.

    • It belongs to a group of medicines called “neurokinin 1 (NK 1 ) receptor antagonists”.

    • The brain has a specific area that controls nausea and vomiting. EMETEND 150 mg works by blocking signals to that area, thereby reducing nausea and vomiting.

    • It is used in combination with other medicines to prevent nausea and vomiting caused by cancer treatment (chemotherapy).

    2. What you need to know before you use EMETEND 150 mg

    EMETEND 150 mg should not be administered to you:

    • • if you are hypersensitive (allergic) to fosaprepitant or any of the other ingredients of EMETEND 150 mg (listed in section 6).
    • • if you are taking pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions) or cisapride (used for treating digestive problems).
    • • If you are pregnant or breastfeeding.
    • • If you are under 18 years of age.

    Warnings and precautions

    Tell your doctor or healthcare professional before being given the injection:

    Special care should be taken with EMETEND 150 mg:

    • • if you have liver disease because the liver is important in breaking down the medicine in the body. Your doctor may have to monitor the condition of your liver.
    • • if you experience redness of the skin or difficulty in breathing whilst or soon after being administered EMETEND 150 mg.

    Children and adolescents

    EMETEND 150 mg should not be given to children and adolescents under 18 years of age, as it has not been studied in this population.

    Other medicines and EMETEND 150 mg

    Always tell your healthcare provider if you are taking any other medicine. (This includes complementary or traditional medicines.)

    An infusion of EMETEND 150 mg can affect other medicines and taking other medicines while using fosaprepitant might affect how fosaprepitant works.

    The effects of EMETEND 150 mg or other medicines may be increased or decreased when taken together.

    Please talk to your doctor or pharmacist if you are taking any of the following medicines:

    • o birth control medicines as they may not work effectively when taken together with fosaprepitant. Additional non-hormonal birth control should be used while on treatment with fosaprepitant and for one month after treatment
    • o ciclosporin, tacrolimus, sirolimus, everolimus (medicines that decrease the body’s immune response)
    • o alfentanil, fentanyl (used to treat pain)
    • o quinidine (used to treat irregular heartbeat)
    • o irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer)
    • o medicines containing ergot alkaloid derivatives such as ergotamine and dihydroergotamine (used for treating migraines)
    • o warfarin, acenocoumarol (blood thinners; blood tests may be required)
    • o rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections)
    • o phenytoin (a medicine used to treat seizures)
    • o carbamazepine (used to treat depression and epilepsy)
    • o midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep)
    • o St. John’s Wort (a herbal preparation used to treat depression)
    • o protease inhibitors (used to treat HIV infections)
    • o ketoconazole except shampoo (used to treat Cushing’s syndrome – when the body produces an excess of cortisol)
    • o itraconazole, voriconazole, posaconazole (antifungals)
    • o nefazodone (used to treat depression)
    • o diltiazem (a medicine used to treat high blood pressure)
    • o corticosteroids (such as dexamethasone, methylprednisolone)
    • o anti-anxiety medicines (such as alprazolam)
    • o tolbutamide (a medicine used to treat diabetes)
    • o paroxetine (antidepressant)

    3. How to use EMETEND 150 mg

    • Do not share medicines prescribed for you with any other person.

    • EMETEND 150 mg will be given to as an intravenous infusion (a drip).

    • The powder will be reconstituted and diluted before use.

    • You will not be expected to give yourself EMETEND 150 mg. It will be given to you by a person who is qualified to do so.

    If you take more EMETEND 150 mg than you should

    Since a healthcare professional will administer EMETEND 150 mg, he/she will control the dosage. However, in the event of overdose your doctor will manage the overdose.

    If you forget to take EMETEND 150 mg

    Since a healthcare professional will administer EMETEND 150 mg, it is unlikely that the dose will be missed.

    4. Possible side effects

    • EMETEND 150 mg can have side effects.

    • Not all side effects reported for EMETEND 150 mg are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking EMETEND 150 mg, please consult your doctor, pharmacist or other healthcare professional for advice.

    • If any of the following happens, stop taking EMETEND 150 mg and tell your doctor immediately or go to the casualty department at your nearest hospital:

    • o hives, rash, itching,
    • o difficulty breathing or swallowing,
    • o or a serious decrease of blood pressure

    • These are all very serious side effects. If you have them, you may have had a serious reaction to EMETEND 150 mg. You may need urgent medical attention or hospitalisation.

    • Other side effects that have been reported:

    Frequent side effects

    • ▪ constipation, indigestion,
    • ▪ headache,
    • ▪ tiredness,
    • ▪ loss of appetite,
    • ▪ hiccups,
    • ▪ increased amount of liver enzymes in your blood

    Less frequent side effects

    • ▪ dizziness, sleepiness,
    • ▪ acne, rash, excessive sweating, Stevens-Johnson syndrome
    • ▪ anxiousness,
    • ▪ burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
    • ▪ increased painful or burning urination
    • ▪ weakness, generally feeling unwell
    • ▪ reddening of the face/skin, hot flush,
    • ▪ fast or irregular heartbeats, blood pressure increased
    • ▪ fever with increased risk of infection, lowering of red blood cells,
    • ▪ infusion site pain, infusion-site redness, infusion-site itching, infusion site vein inflammation.
    • ▪ fungal and bacterial infection
    • ▪ extreme thirst
    • ▪ feeling disorientated
    • ▪ difficulty swallowing
    • ▪ eye infection
    • ▪ sensation of ringing in the ears
    • ▪ sneezing, coughing, postnasal drip, throat irritation
    • ▪ stomach distension, hard faeces
    • ▪ muscle weakness / spasms
    • ▪ water retention, discomfort in the chest
    • ▪ increased amount of liver and blood enzymes
    • ▪ changes in blood electrolytes, decrease in weight, glucose in urine

    Unknown frequency side effects

    • ▪ allergic reactions / anaphylactic reaction (skin rash, difficulty breathing, shock)
    • ▪ skin itching / hives (itchy, red, raised bumps on the skin)
    • ▪ immediate allergic reactions

    If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

    Reporting of side effects

    If you get side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects to SAHPRA via the “6.04 Adverse Drug Reaction Reporting Form”, found online under SAHPRA’s publications: https://www.sahpra.org.za/Publications/Index/8. By reporting side effects, you can help provide more information on the safety of EMETEND 150 mg.

    5. How to store EMETEND 150 mg

    • Store all medicines out of reach of children.

    • Store in a refrigerator (2 °C – 8 °C).

    • From a microbiological point of view, the medicinal product should be used immediately.

    • If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 48 hours at 20 to 25 °C.

    Important Disclaimer

    The Emetend 150 mg Solution professional information leaflet below is the property of Accord Healthcare and is provided on Somayeza exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Somayeza serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Unlock Exclusive Features

    To ensure the fastest, most secure experience, this feature is exclusively available on the free Somayeza mobile app.

    Download the App to Unlock
    On This Page
    Emetend 150 mg Solution
    1/-
    Official PDF leaflet

    The patient information text is available above. Load the original PDF only when you need it.

    Somayeza AI
    Hello! I am your medical reading assistant. What would you like to know about this patient information leaflet?
    Successfully Stashed! 💊

    This patient information leaflet has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites